Could ozempic help cystic fibrosis diabetes? tiny study hints at yes

NCT ID NCT05788965

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This pilot study tested the drug semaglutide (a GLP-1 receptor agonist, like Ozempic) in 8 overweight or obese adults with cystic fibrosis-related diabetes who were already using insulin. The goal was to see if adding semaglutide could safely help with weight loss and improve blood sugar control over 12 weeks. Because it was a small, open-label study with no comparison group, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
semaglutide (a GLP-1 receptor agonist, also known as Ozempic/Wegovy)
What this could lead to
If it works, this could point toward a new add-on treatment to help manage weight and blood sugar in people with cystic fibrosis-related diabetes.
What could go wrong
This is a very small pilot study with only 8 participants, no placebo group, and short follow-up. Results may not apply to all patients, and side effects like nausea or gastrointestinal issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.